Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | |||||||||||||
Title | Kanjinti (Trastuzumab-anns) FDA Drug Label | ||||||||||||
|
|||||||||||||
URL | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761073 | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Trastuzumab-anns | Trastuzumab-anns | 0 | 0 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Trastuzumab-anns | Kanjinti | ABP 980 | HER2 (ERBB2) Antibody 72 | Kanjinti (Trastuzumab-anns) is a Herceptin (trastuzumab) biosimilar that binds to Erbb2 (Her2), which potentially results in anti-tumor immune response against Erbb2 (Her2)-positive tumors (PMID: 31798693). Kanjinti (Trastuzumab-anns) is FDA approved for use in patients with Erbb2 (Her2) overexpressing breast, metastatic gastric or gastroesophageal junction adenocarcinoma (FDA.gov). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|